Loading...
•
Jun 30, 2024
Amneal Q2 2024 Earnings Report
Amneal announced FDA approval for CREXONT® for Parkinson’s disease treatment.
Key Takeaways
Amneal Pharmaceuticals received U.S. FDA approval for CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT is designed to provide a longer duration of 'Good On' time with less frequent dosing compared to immediate-release CD/LD. The commercial launch is planned for September 2024.
CREXONT approved by FDA for Parkinson's disease treatment.
CREXONT delivers more 'Good On' time with less frequent dosing compared to immediate-release CD/LD.
Commercial launch planned in September 2024.
CREXONT consists of IR granules and ER pellets for rapid onset and long-lasting efficacy.
Revenue by Segment
Forward Guidance
Amneal expects to make CREXONT available to patients in the U.S. in September 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...